hotspot -WSS

hotspot

author：hotspot 2025-10-01 18:08:07 - browse：1239

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Medicare coverage of Wegovy, once blocked, now looks possible

explore

WSS

John Green on his newest strategy for fighting tuberculosis

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

What the airline industry can learn from medicine

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

First U.S. drug developed to treat liver disease MASH is approved

Scientists inch closer to single

entertainment

hotspot

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

‘Oppenheimer’ and the risks of AI in health care

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why scientists need input from humanists on sensitive research

Drug repurposing or repositioning? The language matters

HHS secretary Becerra pressed on Change HealthCare cyberattack

Supreme Court strikes down use of affirmative action

Lawsuit alleges UnitedHealth Group unit illegally denied claims

explore

Why scientists need input from humanists on sensitive research

Infectious disease expert Jeanne Marrazzo assumes Fauci role

What the US credit downgrade means for the economy, your finances

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Adults seen as increasingly susceptible to measles

focus

explore

focus

knowledge